Choose your preferred way to stay informed of new case launches and settlement deadlines
Repare Therapeutics issued a press release, on February 12, 2024, "announc[ing] . . . that it will regain global development and commercialization rights to camonsertib (RP-3500), a potential best-in-class oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase), following termination of its collaboration agreement with Roche." The press release stated that "Roche notified Repare that, effective May 7, 2024, it is terminating its worldwide license and collaboration agreement for the development and commercialization of camonsertib following a review of Roche's pipeline and evolving external factors." Following this news, on February 13, 2024, Repare's stock price fell over 15%.
In order to be eligible to join the RPTX class action lawsuit, you must have incurred a loss on shares of Repare Therapeutics purchased during the class period listed above.
TOP
